1 / 8

Update on HIV Cure Research

Update on HIV Cure Research. Robert F. Siliciano , MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland. FORMATTED: 11/17/15. New Orleans, Louisiana: December 15-17, 2015. Slow decay of the reservoir. t 1/2 = 44 months. Siliciano et al.,

lpierce
Download Presentation

Update on HIV Cure Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Update on HIV Cure Research Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland FORMATTED: 11/17/15 New Orleans, Louisiana: December 15-17, 2015

  2. Slow decay of the reservoir t1/2 = 44 months Siliciano et al., Nature Med., 2003 t1/2 = 43 months Crook et al, JID 2015

  3. Approaches to HIV cure Gene Rx TCR pathway agonists † † † † LRAs (HDACi) Prevent reactivation Shock and kill Induce elite control

  4. Current status of LRA trials • Numerous LRAs identified in studies with transformed cell lines and primary T cell model systems • Few shown to work ex vivo with cells from patients TCR pathway agonists † • In clinical trials, no reduction in the reservoir yet demonstrated † LRAs (HDACi) • In clinical trials, evidence for increases in cell-associated HIV RNA (Archin et al.) † • Some evidence for slight transient increases in plasma HIV RNA after LRA treatment (romidepsin, panobinostat, TLR7 agonist)

  5. Assays for latent HIV TCR agonist • Viral outgrowth • assay (VOA) PCR for proviral DNA • DNA PCR TCR agonist • Induction of HIV RNA Measure intracellular HIV RNA TCR agonist • Induction of virion production Measure virion release

  6. Take home points • There is no clinical assay for the latent reservoir • DNA PCR assays widely used for reservoir analysis mainly defect grossly defective proviruses • The quantitative viral outgrowth assay remains the best available assay for the latent reservoir, but better assays are urgently needed. • Other approaches: transient blips following LRA administration, time to rebound after ART interruption

  7. Time to rebound Miss. baby 6 Boston pt. A Boston pt. B 5 Berlin pt. 4 Chun et al. Log reduction in latent reservoir 3 2 1 1 wk 1 mo 3 mo 1 yr 10 yr Lifetime Time to rebound Hill et al, PNAS 2014

  8. What will cure look like? 1,000,000 Therapeutic vaccination 100,000 cART cLRAs 10,000 Plasma HIV RNA (copies/ml) 1000 100 (weeks) (years) Time Post Infection

More Related